nach oben

Erschienen in:

22.12.2017 | Original Communication

Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

verfasst von: Jessica Frau, Luisa Maria Villar, Claudia Sardu, Maria Antonietta Secci, Lucia Schirru, Diana Ferraro, Giancarlo Coghe, Lorena Lorefice, Giuseppe Fenu, Roberta Bedin, Patrizia Sola, Maria Giovanna Marrosu, Eleonora Cocco

Erschienen in: Journal of Neurology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Oligoclonal IgM (OCMB) and IgG (OCGB) bands were found to be associated with poor multiple sclerosis (MS) prognosis.

Objective

We aimed to evaluate the prognostic value of OCMB/OCGB in a cohort of Sardinian MS patients.

Materials and methods

We recruited patients from the University of Cagliari. They underwent lumbar puncture for diagnostic purposes. Demographic and the following clinical data were recorded: clinical course; time to reach EDSS 3 and 6; EDSS at last follow-up; and MS treatments. The influence of gender, clinical course, age at onset, treatments, and OCGB/OCMB on reaching EDSS 3 was analysed using Cox regression. Kaplan–Meier curves were used to study the time to reach EDSS 3 considering OCMB/OCGB and therapies.

Results

The enrolled number of subjects was 503. The variables influencing the achievement of EDSS 3.0 were: male gender (p = 0.005); progressive course (p = 0.001); age at onset (p < 0.001); and disease-modifying drugs (p < 0.001). The OCGB/OCMB status was not significant. Kaplan–Meier analysis showed no difference in time to reach EDSS 3 for patients with and without OCGB or OCMB in both treated and non-treated groups.

Conclusion

Our study did not confirm the poor prognostic value of OCMB/OCGB. These results may be influenced by the peculiar genetic background associated with the risk of MS in Sardinians.

Esiri MM (1977) Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 2:478CrossRefPubMed

Prineas JW, Connell F (1978) The fine structure of chronically active multiple sclerosis plaques. Neurology 28:68–75CrossRefPubMed

Serafini B, Rosicarelli B, Magliozzi R et al (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164–174CrossRefPubMed

Kabat EA, Glusman M, Knaub V (1948) Immunochemical estimation of albumin and gamma globulin in normal and pathological cerebrospinal fluid. Fed Proc 7:306PubMed

Losy J, Metha PD, Wisniewski HM (1990) Identification of IgG subclasses oligoclonal bands in multiple sclerosis. Acta Neurol Scand 82:4–8CrossRefPubMed

Owens GP, Bennett JL, Lassmann H et al (2009) Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 65:639–649CrossRefPubMedPubMedCentral

Cepok S, von Geldern G, Grummel V et al (2006) Accumulation of class switched IgD-IgM-memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol 180:33–39CrossRefPubMed

Tintorè M, Rovira A, Rio J et al (2015) Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138:1863–1874CrossRefPubMed

Villar LM, Masjuan J, Gonzalez-Porqué P et al (2002) Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 58:824–826CrossRefPubMed

10.

Villar LM, Garcia-Barragan N, Espino M et al (2008) Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 14:183–187CrossRefPubMed

11.

Villar LM, Sabada MC, Roldan E et al (2005) Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115:187–194CrossRefPubMedPubMedCentral

12.

Sellebjerg F, Christiansen M, Garred P (1998) MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Mult Scler 4:127–131CrossRefPubMed

13.

Ferquin ST, Barkhof F, Lamers KJ et al (1992) CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand 86:291–297CrossRef

14.

Villar LM, Masjuan J, Gonzalez-Porqué P et al (2002) Intrathecal IgM synthesis predicts the inset of new relapses and a worse disease course in MS. Neurology 59:555–559CrossRefPubMed

15.

Villar LM, Masjuan J, Gonzalez-Porqué P et al (2003) Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 53:222–226CrossRefPubMed

16.

Thangarajh M, Gomez-Rial J, Hedstrom AK et al (2008) Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 14:1208–1213CrossRefPubMed

17.

Mandrioli J, Sola P, Bedin R et al (2008) A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 255:1023–1031CrossRefPubMed

18.

Sharief MK, Thompson EJ (1991) Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain 114:181–195PubMed

19.

Di Pauli F, Gredler V, Kuenz B et al (2010) Features of intrathecal immunoglobulins in patients with multiple sclerosis. J Neurol Sci 15:147–150CrossRef

20.

Schneider R, Euler B, Rauer S (2007) Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol 14:907–911CrossRefPubMed

21.

Boscà I, Magraner MJ, Coret F et al (2010) The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. J Neuroimmunol 226:143–146CrossRefPubMed

22.

Ferraro D, Simone AM, Bedin R et al (2013) Cerebrospinal fluid oligoclonal IgM bands oredict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol 257:76–81CrossRefPubMed

23.

Durante L, Zaaroui W, Rico A et al (2012) Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler 18:587–591CrossRefPubMed

24.

Villar LM, Espino M, Cavanillas ML et al (2010) Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clin Immunol 137:51–59CrossRefPubMed

25.

Garcia-Barragan N, Villar LM, Espino M et al (2009) Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur J Neurol 16:380–385CrossRefPubMed

26.

Frau J, Cossu D, Coghe G et al (2013) Mycobacterium avium subsp. paratubercolosis and multiple sclerosis in Sardinian patients: epidemiology and clinical features. Mult Scler 19:1437–1442CrossRefPubMed

27.

Cocco E, Sardu C, Pieroni E et al (2012) HLA-DRB1-DQB1 haplotypes confer susceptibility and resistance to multiple sclerosis in Sardinia. PLoS ONE 7:e33972CrossRefPubMedPubMedCentral

28.

Steri M, Orrù V, Idda ML et al (2017) Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med 376:1615–1626CrossRefPubMedPubMedCentral

29.

Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefPubMedPubMedCentral

30.

Merkel B, Butzkueven H, Traboulsee AL et al (2017) Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev 16:658–665CrossRefPubMed

31.

Buck D, Albrecht E, Aslam M et al (2013) Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol 73:86–94CrossRefPubMed

32.

Delgado-Garcia M, Matesanz F, Alcina A et al (2015) A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands. Mult Scler 21(9):1104–1111CrossRefPubMed

33.

Goris A, Pauwels I, Gustavsen MW et al (2015) Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain 138:632–643CrossRefPubMedPubMedCentral

Titel: Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
verfasst von: Jessica Frau
Luisa Maria Villar
Claudia Sardu
Maria Antonietta Secci
Lucia Schirru
Diana Ferraro
Giancarlo Coghe
Lorena Lorefice
Giuseppe Fenu
Roberta Bedin
Patrizia Sola
Maria Giovanna Marrosu
Eleonora Cocco
Publikationsdatum: 22.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 2/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8716-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Abstract

Background

Objective

Materials and methods

Results

Conclusion

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Background

Objective

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Low intrathecal antibody production despite high seroprevalence of Epstein–Barr virus in multiple sclerosis: a review of the literature

Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials

Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim–Chester disease

Long-term follow-up more than 10 years after HSCT: a monocentric experience

INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin

Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie